Cerchietti, Leandro

Publications

Sort by

Co-Author Network

selected publications

Profiling Dynamic Patterns of Single-Cell Motility. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2024 Academic Article GET IT
Author Correction: A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. 2024 GET IT
Germinal Center Dark Zone harbors ATR-dependent determinants of T-cell exclusion that are also identified in aggressive lymphoma. 2024 GET IT
XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells. Cancer research. 2024 Academic Article GET IT
Times cited: 6
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 Academic Article GET IT
Times cited: 29
Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma. Nature medicine. 2023 Academic Article GET IT
The eukaryotic translation initiation factor eIF4E reprograms alternative splicing. The EMBO journal. 2023 Academic Article GET IT
Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular cancer therapeutics. 2022 Academic Article GET IT
Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities. Blood. 2022 Academic Article GET IT
Precise reconstruction of the TME using bulk RNA-seq and a machine learning algorithm trained on artificial transcriptomes. Cancer cell. 2022 Academic Article GET IT
Variational autoencoders learn transferrable representations of metabolomics data. Communications biology. 2022 Academic Article GET IT
BCL10 mutations define distinct dependencies guiding precision therapy for DLBCL. Cancer discovery. 2022 Academic Article GET IT
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL. Blood. 2022 Academic Article GET IT
Times cited: 23
Histamine H4 Receptor Agonism Induces Antitumor Effects in Human T-Cell Lymphoma. International journal of molecular sciences. 2022 Academic Article GET IT
Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. Blood cancer discovery. 2021 Academic Article GET IT
The metabolic adaptation evoked by arginine enhances the effect of radiation in brain metastases. Science advances. 2021 Academic Article GET IT
SWOG 1918: A phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed aggressive non-Hodgkin lymphomas - Aiming to improve therapy, outcomes, and validate a prospective frailty tool. Journal of geriatric oncology. 2021 Academic Article GET IT
Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas. Cancer research. 2021 Academic Article GET IT
Times cited: 19
Characterization of GECPAR, a noncoding RNA that regulates the transcriptional program of diffuse large B cell lymphoma. Haematologica. 2021 Academic Article GET IT
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer discovery. 2021 Academic Article GET IT
Times cited: 124
The eukaryotic translation initiation factor eIF4E elevates steady-state m⁷G capping of coding and noncoding transcripts. Proceedings of the National Academy of Sciences of the United States of America. 2020 Academic Article GET IT
Times cited: 30
Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Scientific reports. 2020 Academic Article GET IT
A Novel JAK1 Mutant Breast Implant-Associated Anaplastic Large Cell Lymphoma Patient-Derived Xenograft Fostering Pre-Clinical Discoveries. Cancers. 2020 Academic Article GET IT
Limits in the detection of m⁶A changes using MeRIP/m⁶A-seq. Scientific reports. 2020 Academic Article GET IT
Times cited: 135
Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell reports. 2020 Academic Article GET IT
Times cited: 14
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 86
Thyroid hormones induce doxorubicin chemosensitivity through enzymes involved in chemotherapy metabolism in lymphoma T cells. Oncotarget. 2019 Academic Article GET IT
BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. Cancer discovery. 2019 Academic Article GET IT
Times cited: 32
Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma. Blood. 2018 Academic Article GET IT
Times cited: 93
Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer research. 2018 Academic Article GET IT
Times cited: 59
Metabolomic Profiling Reveals Cellular Reprogramming of B-Cell Lymphoma by a Lysine Deacetylase Inhibitor through the Choline Pathway. EBioMedicine. 2018 Academic Article GET IT
Times cited: 25
The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data^. Leukemia & lymphoma. 2017 Letter GET IT
Times cited: 4
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature genetics. 2017 Academic Article GET IT
Times cited: 71
Award Winner in the Young Investigator Category, 2017 Society for Biomaterials Annual Meeting and Exposition, Minneapolis, MN, April 05-08, 2017: Lymph node stiffness-mimicking hydrogels regulate human B-cell lymphoma growth and cell surface receptor expression in a molecular subtype-specific manner. Journal of biomedical materials research. Part A. 2017 Academic Article GET IT
Times cited: 9
Combination Therapy Targeting BCL6 and Phospho-STAT3 Defeats Intratumor Heterogeneity in a Subset of Non-Small Cell Lung Cancers. Cancer research. 2017 Academic Article GET IT
Times cited: 32
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer discovery. 2017 Academic Article GET IT
Times cited: 40
THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors. Nature communications. 2017 Academic Article GET IT
Times cited: 72
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. Cancer research. 2017 Academic Article GET IT
Times cited: 14
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Oncotarget. 2016 Academic Article GET IT
Times cited: 19
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 202
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 131
Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients. Clinical epigenetics. 2016 Academic Article GET IT
Times cited: 39
Therapeutic implication of concomitant chromosomal aberrations in patients with aggressive B-cell lymphomas. Cell cycle (Georgetown, Tex.). 2016 Academic Article GET IT
Times cited: 7
Increased protein processing gene signature in HDACi-resistant cells predicts response to proteasome inhibitors. Leukemia & lymphoma. 2016 Article GET IT
Times cited: 1
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 27
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. 2015 Academic Article GET IT
Times cited: 70
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 36
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 2015 Academic Article GET IT
Times cited: 63
High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells. Cancer letters. 2015 Academic Article GET IT
Times cited: 12
Ex vivo engineered immune organoids for controlled germinal center reactions. Biomaterials. 2015 Academic Article GET IT
Times cited: 99
Epigenomic evolution in diffuse large B-cell lymphomas. Nature communications. 2015 Academic Article GET IT
Times cited: 106
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. Leukemia. 2014 Academic Article GET IT
Times cited: 40
Integrin αvβ3 acting as membrane receptor for thyroid hormones mediates angiogenesis in malignant T cells. Blood. 2014 Academic Article GET IT
Times cited: 77
Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. Breast cancer research : BCR. 2014 Academic Article GET IT
Times cited: 28
Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and molecular bioengineering. 2014 Academic Article GET IT
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Academic Article GET IT
Times cited: 134
Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS chemical biology. 2014 Academic Article GET IT
Times cited: 21
The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014 Academic Article GET IT
Times cited: 159
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 2014 Academic Article GET IT
Times cited: 64
Mir-592 regulates the induction and cell death-promoting activity of p75NTR in neuronal ischemic injury. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2014 Academic Article GET IT
Times cited: 82
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery. 2013 Academic Article GET IT
Times cited: 167
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013 Academic Article GET IT
Times cited: 63
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell reports. 2013 Academic Article GET IT
Times cited: 149
The metabolism of lymphomas. Current opinion in hematology. 2013 Information Resource GET IT
Times cited: 10
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 673
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Academic Article GET IT
Times cited: 73
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS genetics. 2013 Academic Article GET IT
Times cited: 101
Targeting the epigenome and other new strategies in diffuse large B-cell lymphoma: beyond R-CHOP. Hematology. American Society of Hematology. Education Program. 2013 Review GET IT
Times cited: 18
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer cell. 2012 Academic Article GET IT
Times cited: 210
The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell metabolism. 2012 Academic Article GET IT
Times cited: 102
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature chemical biology. 2011 Academic Article GET IT
Times cited: 232
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 157
Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Academic Article GET IT
Times cited: 53
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Academic Article GET IT
Times cited: 128
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 Academic Article GET IT
Times cited: 168
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PloS one. 2011 Academic Article GET IT
Times cited: 45
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 101
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010 Academic Article GET IT
Times cited: 131
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 39
BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of experimental medicine. 2010 Academic Article GET IT
Times cited: 103
Morphine versus midazolam as upfront therapy to control dyspnea perception in cancer patients while its underlying cause is sought or treated. Journal of pain and symptom management. 2010 Academic Article GET IT
Times cited: 60
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer cell. 2010 Academic Article GET IT
Times cited: 254
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature medicine. 2009 Academic Article GET IT
Times cited: 146
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 280
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009 Academic Article GET IT
Times cited: 191
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2008 Academic Article GET IT
Times cited: 153
Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer research. 2008 Academic Article GET IT
Times cited: 27
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Molecular cell. 2008 Academic Article GET IT
Times cited: 133
Continuous hyperfractionated accelerated radiation therapy week-end less in combination with neoadjuvant chemotherapy for the treatment of stage III non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2007 Academic Article GET IT
Times cited: 8
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 121
Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Nutrition and cancer. 2007 Academic Article GET IT
Morphine mouthwashes for painful mucositis. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 2006 Article GET IT
Times cited: 7
Double-blinded, placebo-controlled trial on intravenous L-alanyl-L-glutamine in the incidence of oral mucositis following chemoradiotherapy in patients with head-and-neck cancer. International journal of radiation oncology, biology, physics. 2006 Academic Article GET IT
Times cited: 85
Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin. Cancer investigation. 2006 Academic Article GET IT
Times cited: 21
Kaiso-deficient mice show resistance to intestinal cancer. Molecular and cellular biology. 2006 Academic Article GET IT
Times cited: 141
Midazolam as adjunct therapy to morphine in the alleviation of severe dyspnea perception in patients with advanced cancer. Journal of pain and symptom management. 2006 Academic Article GET IT
Times cited: 150
Phase I/II study of selective cyclooxygenase-2 inhibitor celecoxib as a radiation sensitizer in patients with unresectable brain metastases. Journal of neuro-oncology. 2005 Academic Article GET IT
Times cited: 36
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature medicine. 2004 Academic Article GET IT
Times cited: 226
Effects of celecoxib, medroxyprogesterone, and dietary intervention on systemic syndromes in patients with advanced lung adenocarcinoma: a pilot study. Journal of pain and symptom management. 2004 Article GET IT
Times cited: 51
Potential utility of the peripheral analgesic properties of morphine in stomatitis-related pain: a pilot study. Pain. 2003 Academic Article GET IT
Times cited: 79
Effect of topical morphine for mucositis-associated pain following concomitant chemoradiotherapy for head and neck carcinoma. Cancer. 2002 Academic Article GET IT
Times cited: 124
Conventional chest radiography in the initial assessment of adult cancer patients with fever and neutropenia. Cancer control : journal of the Moffitt Cancer Center. 2002 Academic Article GET IT
Times cited: 19
Hypodermoclysis for control of dehydration in terminal-stage cancer. International journal of palliative nursing. 2000 Academic Article GET IT
Times cited: 55

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche awarded by National Cancer Institute Principal Investigator 2024 - 2029
Targeting the microenvironment to increase immunity and immunotherapy response in DLBCL awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2024 - 2027
Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies awarded by National Cancer Institute Principal Investigator 2020 - 2025
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape awarded by National Cancer Institute Principal Investigator 2022 - 2024
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape awarded by National Cancer Institute Principal Investigator 2019 - 2024

Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Co-Principal Investigator 2022 - 2027

more ...

less ...

Background

education and training

M.D., University of Salvador, Faculty of Medicine (Argentina) 96

Contact

full name

Leandro Cerchietti

primary email

lec2010@med.cornell.edu

VIVO Weill Cornell Medical College

Leandro Cerchietti Associate Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email